RXST Quote, Financials, Valuation and Earnings

Picard Medical has a net margin of -32.35% compared to RxSight, Inc.'s net margin of --. RxSight, Inc.'s return on equity of -12.84% beat Picard Medical's return on equity of --.

RxSight, Inc. has a consensus price target of $10.00, signalling downside risk potential of -21.64%. On the other hand Picard Medical has an analysts' consensus of -- which suggests that it could fall by --. Given that RxSight, Inc. has higher upside potential than Picard Medical, analysts believe RxSight, Inc. is more attractive than Picard Medical.

RxSight, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Picard Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

RxSight, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Picard Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight, Inc. pays -- of its earnings as a dividend. Picard Medical pays out -- of its earnings as a dividend.

RxSight, Inc. quarterly revenues are $30.3M, which are larger than Picard Medical quarterly revenues of --. RxSight, Inc.'s net income of -$9.8M is higher than Picard Medical's net income of --. Notably, RxSight, Inc.'s price-to-earnings ratio is -- while Picard Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight, Inc. is 3.61x versus -- for Picard Medical. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -32.35% compared to RxSight, Inc.'s net margin of -862.39%. RxSight, Inc.'s return on equity of -12.84% beat VolitionRX Ltd.'s return on equity of --.

RxSight, Inc. has a consensus price target of $10.00, signalling downside risk potential of -21.64%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.60 which suggests that it could grow by 866.54%. Given that VolitionRX Ltd. has higher upside potential than RxSight, Inc., analysts believe VolitionRX Ltd. is more attractive than RxSight, Inc..

RxSight, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

RxSight, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

RxSight, Inc. quarterly revenues are $30.3M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. RxSight, Inc.'s net income of -$9.8M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, RxSight, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight, Inc. is 3.61x versus 18.43x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision, Inc. has a net margin of -32.35% compared to RxSight, Inc.'s net margin of -1037.17%. RxSight, Inc.'s return on equity of -12.84% beat Catheter Precision, Inc.'s return on equity of -192.05%.

RxSight, Inc. has a consensus price target of $10.00, signalling downside risk potential of -21.64%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1405%. Given that Catheter Precision, Inc. has higher upside potential than RxSight, Inc., analysts believe Catheter Precision, Inc. is more attractive than RxSight, Inc..

RxSight, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.

RxSight, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.

RxSight, Inc. quarterly revenues are $30.3M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. RxSight, Inc.'s net income of -$9.8M is lower than Catheter Precision, Inc.'s net income of -$2.3M. Notably, RxSight, Inc.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight, Inc. is 3.61x versus 11.87x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -32.35% compared to RxSight, Inc.'s net margin of 3.93%. RxSight, Inc.'s return on equity of -12.84% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

RxSight, Inc. has a consensus price target of $10.00, signalling downside risk potential of -21.64%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 106.9%. Given that Xtant Medical Holdings, Inc. has higher upside potential than RxSight, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than RxSight, Inc..

RxSight, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

RxSight, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

RxSight, Inc. quarterly revenues are $30.3M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. RxSight, Inc.'s net income of -$9.8M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, RxSight, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 71.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight, Inc. is 3.61x versus 0.79x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.